novocure®

patientforward

forward-looking statements

In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated.

As of the date of this presentation, Optune Gio is FDA-approved for the treatment of adults with supratentorial glioblastoma (GBM). Optune Lua is FDA-approved for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) and for the treatment of adults with malignant pleural mesothelioma or pleural mesothelioma (MPM),respectively, and the approval for use in other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune Gio or Optune Lua or their successful commercialization and can provide no assurances regarding the company's results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security.

together with our patients,
we strive to extend survival
in some of the most
aggressive forms of cancer

patientforward®

Tumor Treating Fields (TTFields) target the electrical properties of cancer cells





control



TTFields

TTFields are delivered through a portable, wearable medical device

OPTUNE GIO®



OPTUNE LUA®

patientforward®

strong foundation and building towards profitability

approved and reimbursed
IN MAJOR GLOBAL MARKETS

>4,100
GLOBAL GBM ACTIVE PATIENTS ON THERAPY[1]

NCCN Category 1
GUIDELINE RECOMMENDATION IN NEWLY DIAGNOSED GBM

$605M
2024 NET REVENUE

$210M
2024 R&D INVESTMENTS

intellectual property
ROBUST PORTFOLIO WITH ONGOING DEVELOPMENTS

GBM, glioblastoma; LTM, last twelve months; NSCLC, R&D, research and development. 1. As of June 30, 2025.

entering a new era with expanding oncology platform

2025

- ESTABLISHED FOOTPRINT IN GLIOBLASTOMA
- COMMERCIALLY LAUNCHED IN NSCLC
- POSITIVE PHASE 3 DATA IN BRAIN METS FROM NSCLC
- POSITIVE PHASE 3 DATA IN LOCALLY ADV. PANCREATIC CANCER

patientforward®

NSCLC, non-small cell lung cancer; mets, metastases.

TTFields est. as a platform therapy with 4 positive phase 3 trials in cancers with significant unmet need

glioblastoma	non-small cell lung cancer	brain mets from NSCLC	locally advanced pancreatic cancer
Extends OS	Extends OS	Extends TTIP	Extends OS
>$600m Annual revenue[1]	FDA approved & CE mark obtained	Positive top-line data announced	Positive data presented & published
>4,100 Patients on therapy[2]	Commercially launching	H2 2025 Planned regulatory submission	Q3 2025 Planned regulatory submission

patientforward®

1. Full year 2024; 2. As of June 30, 2025. FDA, U.S. Food & Drug Administration; NSCLC, non-small cell lung cancer; OS, overall survival; TTIP, time to intracranial progression.

new indications significantly expand eligible patient population

U.S. ANNUAL DIAGNOSES OF ON-LABEL PATIENTS SEEKING THERAPY



7x

EXPANSION IN TOTAL ADDRESSABLE MARKET FROM NEW INDICATIONS

patientforward®

*Eligible patient population estimates based on patients that would meet inclusion criteria for clinical trial protocol.

first phase 3 trial to extend OS in unresectable, locally advanced pancreatic cancer

PANOVA-3 PHASE 3 CLINCAL TRIAL – OVERALL SURVIVAL



patientforward®

- Late breaking oral abstract featured in 'best of ASCO,' published in JCO
- Anticipate filing regulatory applications in the U.S. in Q3 '25
- PANOVA-4 phase 2 builds on promising data for TTFields with PD-(L)1 inhibitors in metastatic PDAC

CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; OS, overall survival; TTFields, Tumor Treating Fields

statistically significant improvement in pain-free survival exhibited in TTFields + GnP population

PANOVA-3 PHASE 3 CLINCAL TRIAL – PAIN-FREE SURVIVAL*

Median pain-free survival (mo)	15.2	9.1
Log-rank *P*-value	0.027	
HR (95% CI)	HR = 0.74 (95% CI: 0.56, 0.97)	
1-year pain-free survival rate (95% CI)	54.1% (46.2, 61.3)	45.1% (36.8, 53.0)



patientforward®

CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population;; TTFields, Tumor Treating Fields; VAS, visual analogue scale.

2025-2026 anticipated clinical development milestones



2025 key objectives, unlocking TTFields potential

DRIVING COMMERCIAL ADOPTION

- ✓ **NSCLC** drive global active patient growth and pursue reimbursement
- ✓ **NSCLC** CE Mark achieved, launch underway in Germany
- **NSCLC** PMDA approval and launch in Japan

ADVANCING CLINICAL PIPELINE

- ✓ **PANOVA-3** present and publish data
- **PANOVA-3 submit to FDA**, CE Mark and PMDA
- **METIS submit to FDA,** publish clinical data
- **TRIDENT** and **PANOVA-4** patient follow up; prepare for H1 2026 top-line data

DELIVERING PRODUCT INNOVATION

- ✓ Launch **MyNovocure** patient app
- **New array** utilized by every Optune Gio patient
- **Advance next gen** torso array

roadmap to becoming profitable multi-indication oncology company

3

FUTURE EXPANSION
Advance label-expanding clinical trials, investment in platform

2

OPPORTUNITIES ON THE HORIZON
Drive new indications (PANOVA; METIS), further product development

1

NEAR-TERM OPPORTUNITIES
Increase GBM penetration, launch lung, launch new arrays

TODAY*
4,331 active patients

patientforward®

* as of June 30, 2025.





DRIVE | COURAGE | TRUST | patientforward | EMPATHY | INNOVATION | FOCUS



Optune Lua® and Optune Gio® indications for use and important safety information

INDICATIONS

- Optune Lua® is indicated as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
- Optune Lua® is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.
- Optune Gio® is intended as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiforme (GBM).
- Optune Gio with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
- For the treatment of recurrent GBM, Optune Gio is indicated following histologically or radiologically confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

CONTRAINDICATIONS

- Do not use Optune Lua in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.
- Do not use Optune Lua or Optune Gio in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua or Optune Gio may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure, shock, and breathing difficulty, including respiratory failure.
- Do not use Optune Gio in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune Gio together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune Gio together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune Gio ineffective.

Optune Lua® and Optune Gio® indications for use and important safety information

WARNINGS AND PRECAUTIONS

- Optune Lua and Optune Gio can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer).
- Do not prescribe Optune Lua or Optune Gio for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua and Optune Gio in these populations have not been established.
- The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel for mNSCLC were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritis, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia.
- The most common (≥10%) adverse events involving Optune Gio together with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
- The most common (≥10%) adverse events seen with Optune Gio monotherapy were medical device site reaction and headache. Other potential adverse reactions were considered related to Optune Gio when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer.
- Other potential adverse effects associated with the use of Optune Lua for mNSCLC include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer.
- The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy for MPM were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.
- Other potential adverse effects associated with the use of Optune Lua for MPM include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.
- Use of Optune Gio in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune Gio in these patients could lead to tissue damage or lower the chance of Optune Gio being effective.
- If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.
- If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune Gio treatment.
- Please see full Instructions For Use (IFU) for Optune Lua® for mNSCLC at www.optuneluahcp.com.
- Please see full Instructions For Use (IFU) for Optune Lua® for MPM at www.optunelua.com/mpm/.
- Please see full Instructions For Use (IFU) for and Optune Gio® at www.optunegiohcp.com

